UK long-acting bronchodilator market is anticipated to grow at a substantial rate of around 1.5% during the forecast period. Inhalers are used for providing medication to the patients through the lungs. These are used for the treatment of the patient from asthma attacks and other respiratory ailments. As the prevalence of asthma and other diseases increases across UK, the demand for long-acting bronchodilators is also expected to increase for treatment purposes. As per the International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises England, Scotland, Wales and Northern Ireland. The total population of the country in 2017 was 65 million, out of which about 18% are of the geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by the government and people can be forecast in the near future.

Request a Free Sample of our Report on UK Long-Acting Bronchodilator Market https://www.omrglobal.com/request-sample/uk-long-acting-bronchodilator-market

UK long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country and rising demand for its various treatment solutions. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

A full Report of UK Long-Acting Bronchodilator Market is Available at: https://www.omrglobal.com/industry-reports/uk-long-acting-bronchodilator-market

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing long-acting bronchodilator to cater to a wide range of customers within the region and across the globe. The major players of the UK long-acting bronchodilator market include BoehringerIngelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., and Vitalograph Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

UK Long-Acting Bronchodilator Market Segmentation

By Route of Administration

• Oral
• Nasal
• Parenteral
• Inhalation

By Application

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

By End-User

• Homecare
• Hospitals and Clinics

Company Profiles

• Adamis Pharmaceuticals Corp.
• AstraZeneca PLC
• BoehringerIngelheim International GmbH
• GlaxoSmithKline PLC
• Novartis AG
• ResMed Corp.
• Pulmatrix Inc.
• Savara, Inc.
• Sunovion Pharmaceuticals
• Teva Pharmaceuticals Industries Ltd.
• Vitalograph Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-long-acting-bronchodilator-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404